Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...
clinicaladvisor.com

Targeted Antibody Therapy for the Prevention of Type 1 Diabetes and Preservation of Residual β-Cell Function

Teplizumab has shown significant preservation of C-peptide levels in newly diagnosed type 1 diabetes (T1D) patients, indicating the potential for modifying disease progression. Combining teplizumab ...
BioWorld

Anti-CD3 antibody improves motor function in model of spinal cord injury

Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...
Pulmonology Advisor

IPF and Familial Pulmonary Fibrosis Differ in Terms of B and T Cell Distribution

There are differences between familial and idiopathic pulmonary fibrosis in terms of cluster of differentiation 20 and CD3 expression.
ascopubs.org

T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatment of women with stage IV breast cancer (phase I): Clinical and immune function results.

The effect of enoxaparin on inflammatory and thrombotic mediators in cancer patients as studied using protein and biochip array approaches. This is an ASCO Meeting Abstract from the 2011 ASCO Annual ...
manilatimes

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated "brain fog”. BOSTON ...